Member access

4-Traders Homepage  >  Shares  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

294
Delayed Quote. Delayed Euronext Bruxelles - 11/21 11:35:03 am
60.95 EUR   -1.14%
11/13 UCB : Transparency notification of Vanguard Health Care Fund
11/12 UCB : Transparency notification of Vanguard Health Care Fund
11/07 Belgium's UCB to sell generics unit for 964 million pounds
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

UCB : UCBs Executive Committee with two new members

05/25/2011 | 01:15am US/Eastern

• Greg Duncan, Executive Vice President, President of North American Operations

• Jean-Christophe Tellier, MD, Executive Vice President, President of European Operations

Vers la version en français

Naar de nederlandstalige versie

BRUSSELS, 25 May 07:00 (CET) - regulated information - With UCB set to enter its growth phase in 2012 and building on major advances in its late-stage pipeline, UCB announced today that two new members will join the company’s Executive Committee as of July 1, 2011.

The two new members are the heads of the US and European commercial operations, respectively Greg Duncan, currently Senior Vice President and President of UCB’s North American Operations, and Jean-Christophe Tellier, joining UCB from Ipsen.

These additions will allow Mark McDade, UCB’s EVP Global Operations and Chief Operating Officer to focus on UCB’s future growth markets outside the US and Europe, while driving UCB’s commercial growth strategy across all geographies. Mark will also continue to lead Business Development and maintains his global leadership of the company’s Marketing, Access and Medical Affairs functions, preparing the launch and commercialization of the next generation of medicines from UCB’s promising late-stage pipeline, such as brivaracetam in epilepsy, epratuzumab in Lupus and Sclerostin antibody in post-menopausal osteoporosis and fracture healing.

Greg Duncan joined UCB in 2007 to lead UCB’s European Operations. He then became President of European and Emerging Market Operations until 2009 when he was appointed President of UCB’s North American operations. Greg has a degree in Economics from the State University of New York, Albany, and a MBA in Marketing and Management from the Emory University in Atlanta. He started his career in 1989, within Pfizer, where he had spent 17 years holding various managerial positions. His last position within Pfizer was as President Latin America.

Jean-Christophe Tellier is joining UCB from Ipsen where he was President & General Manager Ipsen US. His role at Ipsen was to strengthen Ipsen’s specialty care business in North America, in the areas of endocrinology and neurology. Prior to joining Ipsen in May 2009, he was Executive Vice President and Chief Commercial Officer at MacroGenics Inc, a Maryland-based biotechnology company. Jean-Christophe Tellier spent the largest part of his career at Novartis (Ciba) where he held several commercial operations roles in France, Belgium and Switzerland. Jean-Christophe Tellier is a physician specialized in rheumatology (University of Paris V, France).

Detailed biographies of the members of the Executive Committee can be found on UCB’s website.

For further Information:

Antje Witte, Investor Relations, UCB

T +32.2.559.9414,

Michael Tuck-Sherman, Investor Relations, UCB

T +32.2.559.9712, Michael.tuck-sherman@ucb.comantje.witte@ucb.com

About UCB

UCB, Brussels, Belgium () is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9000 people in over 40 countries, UCB produced revenue of EUR 3.22 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

www.ucb.com

UCB Media Room

e: UCB.MediaRoom@ucb.com

React to this article
Latest news on UCB
11/13 UCB : Transparency notification of Vanguard Health Care Fund
11/12 UCB : Transparency notification of Vanguard Health Care Fund
11/07 Belgium's UCB to sell generics unit for 964 million pounds
10/22 EXCLUSIVE- ADVENT, AVISTA NEAR DEAL : sources
10/21UCB SA : quaterly earnings release
10/08 UCB : Georgia Bio and UCB to Host Parkinson's Gala Benefitting the National Park..
09/26 UCB : Acquisition of own shares
09/24 UCB : Patent Application Titled "Systems and Methods for Administering Medicatio..
09/23 Pending 'inversions' that new U.S. Treasury rules may hit
09/17 UCB : Patent Issued for Method for Producing Protein
Advertisement
Chart
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF